Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2023.02.040
- Author:
Li-Yua ZHOU
1
;
Li-Yua ZHOU
2
Author Information
1. Graduate School of Qinghai University, Xining 810001, Qinghai Province, China.
2. Department of Hematology, Nanjing Lishui People's Hospital/Zhong Da Hospital Lishui Branch, Southeast Universiy, Najing 211200, Jiangsu Province, China.E-mail: xhx-73@163.com.
- Publication Type:Review
- Keywords:
chronic myeloid leukemia;
mutation;
tyrosine kinase inhibitor
- MeSH:
Humans;
Antineoplastic Agents/pharmacology*;
Dasatinib/pharmacology*;
Drug Resistance, Neoplasm/genetics*;
Fusion Proteins, bcr-abl/genetics*;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(2):585-588
- CountryChina
- Language:Chinese
-
Abstract:
The treatment of chronic myeloid leukemia (CML) was revolutionized with the advent of the first-generation tyrosine kinase inhibitors (TKIs), but drug resistance developed during treatment, leading to the development of the second-generation (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKI. Compared with previous treatment regimens, specific TKI can significantly improve the response rate, overall survival rate and prognosis of CML. Only a few patients with BCR-ABL mutation are insensitive to the second-generation TKIs, so it is suggested to select the second-generation TKIs for patients with specific mutations. For patients with other mutations and without mutations, the second-generation TKI should be selected according to the patient's medical history, while the third-generation TKIs should be selected for mutations that are insensitive to the second-generation TKIs, such as T315I mutation that is sensitive to ponatinib. Due to different BCR-ABL mutations in patients with different sensitivity to the second and third-generation TKIs, this paper will review the latest research progress of the efficacy of the second and third-generation TKIs in CML patients with BCR-ABL mutations.
